 |
Pembrolizumab |
|---|---|
| Trade Name | Keytruda |
| Orphan Indication | Small Cell Lung Cancer excluding those that have been identified as having a biomarker referred to as microsatellite instability-high (MSI-H) or mismatched repair deficient (dMMR) |
| USA Market Approval | USA |
| USA Designation Date | 2017-10-03 00:00:00 |
| Sponsor | Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc.;1 Merck Drive;Whitehouse Station, New Jersey, 08889 |
